Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy
about
Pancreatic cancer stem cell markers and exosomes - the incentive pushNeoadjuvant therapy for localized pancreatic cancer: guiding principlesPancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p.Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer.Pancreatic cancer and FOLFIRINOX: a new era and new questions.Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice GuidelinePre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancerComparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with tumor cell.Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter studyThe concept of 'borderline resectable' pancreatic cancer: limited foundations and limited future?Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy.Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods.Biomarkers for early diagnosis of pancreatic cancer.Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial.Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy?Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.Pancreatic ductal adenocarcinoma: is a cure possible?FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma.Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis.Improved Survival in Patients with Resected Pancreatic Carcinoma Using Postoperative Intensity-Modulated Radiotherapy and Regional Intra-Arterial Infusion Chemotherapy.Synergistic effect of a drug loaded electrospun patch and systemic chemotherapy in pancreatic cancer xenograft.Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients.Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer.Extrapancreatic perineural invasion in pancreatic adenocarcinoma.Epidurals in Pancreatic Resection Outcomes (E-PRO) study: protocol for a randomised controlled trial.The independent effect of cancer on outcomes: a potential limitation of surgical risk prediction.MiR-21-mediated Metabolic Alteration of Cancer-associated Fibroblasts and Its Effect on Pancreatic Cancer Cell Behavior.Role of Gene Therapy in Pancreatic Cancer-A Review.Reconsideration about the aggressive surgery for resectable pancreatic cancer: a focus on real pathological portosplenomesenteric venous invasion.Targeting pancreatic cancer using a combination of gemcitabine with the omega-3 polyunsaturated fatty acid emulsion, Lipidem™.
P2860
Q26741215-BE4E9C8B-A267-4BF8-8842-826ACD07BEB0Q26799428-D47B2838-98FB-4744-95E7-03021AA70494Q27340831-A4B34AE3-C00F-4126-B241-97BDCB7E779CQ30249814-6C04BFEB-B9D0-47E0-864D-03A50FE86668Q35755386-283AC7A4-4DB6-46D2-BCDD-9AD67D2D6D91Q36035888-10A67C53-2C04-4D7A-B403-957F55191D0EQ36064780-6DAEDD25-5601-4C30-9FA8-6E4C861A0115Q37071139-5C1083CC-6D93-45C6-A0DA-B4A18318DD26Q37520294-8949FE5A-1C62-4EDE-BB58-6D3F5DFB33D4Q37677535-E7A2F6C0-BA99-4534-A7D4-60238A37A5E2Q37698616-A7D946FC-EE21-4BFC-A63E-7A777AE7ABB8Q38263106-AF0831BD-9085-4D04-AA06-33EC72AD58A2Q38265405-E8F78472-3FE1-479E-AD19-554B0D792EA8Q38371662-84B5C1A7-06E5-4DBF-A5A3-8478BF5CABACQ38604399-86E912DA-23CC-4171-89D7-8EBC7F1738C6Q38694488-625B921C-F2C7-4731-BB8B-605F764A266CQ38749836-129016D1-A7A3-4298-B125-5565043D2C5FQ38910968-92FC73B3-E53A-4ED0-91B2-CCAEC0A1267FQ39371358-00252E6C-D325-4E20-9534-D3D33DA9864DQ40729761-1C4222C3-38B5-41A1-9773-2C5A69A6E60EQ41863407-215F9FCE-5FBD-4AF1-8F4B-3508527FE257Q42366470-37AE3EFF-AE0D-4AC2-A1FA-298F2C5FBA35Q42374126-D1AEED0B-D84D-438E-B94F-B487DA56C09CQ47192923-341037B9-4C37-4CCC-B56E-8E74D39696DDQ47749335-108139F2-7B0D-4F1A-BC55-F1B2454B15ACQ49644160-2469BFD8-5084-4C6D-9141-BAA2519B43C1Q50037919-0096AD13-F8B4-499E-AAAE-3C58A41BFFB1Q50282306-1B22FA3B-A352-407C-A961-C5574CDB5E9FQ52610258-974942D7-3A02-404D-B18A-3A56F3B016D5Q53519369-8682A960-D870-4C39-9B1B-82B36714A539Q54232104-86492D12-2D95-4CC9-85D5-2B88895EA778
P2860
Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy
@ast
Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy
@en
Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy
@nl
type
label
Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy
@ast
Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy
@en
Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy
@nl
prefLabel
Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy
@ast
Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy
@en
Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy
@nl
P2093
P2860
P3181
P356
P1476
Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy
@en
P2093
Davendra P S Sohal
R Matthew Walsh
Ramesh K Ramanathan
P2860
P304
P3181
P356
10.1093/JNCI/DJU011
P407
P577
2014-02-22T00:00:00Z